Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab vs physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma
KCT0003104Phase 2
Key facts
- Status
- Completed
- Start
- Dec 2018
- Countries
- 1
- Sponsor
- National University Hospital
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Drugs
- durvalumab
- Conditions
- clear cell ovarian cancer
01
Overview
Phase 2, randomised trial of durvalumab in clear cell ovarian cancer (2 arms), sponsored by National University Hospital. Started Dec 2018; status: completed.
02
Design
2 arms- Study design
- Randomized
Durvalumab
Patients receive durvalumab (MEDI4736) as single-agent immunotherapy.
Physician’s choice chemotherapy
Patients receive a chemotherapy regimen selected by the treating physician as standard care for recurrent ovarian clear cell adenocarcinoma.
Beyond the preview
Go deeper on KCT0003104.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003104.